Is NUVL or OBIO more undervalued in 2026?

CirclFi compares Nuvalent, Inc. (NUVL) and Orchestra BioMed Holdings, Inc. (OBIO) using 13 institutional-grade valuation models. NUVL has a Quality of Company score of 3.7/10 while OBIO scores 6.0/10.

Which is a better buy — NUVL or OBIO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NUVL and OBIO valuations compare?

NUVL at $109.27 and OBIO at $3.98 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NUVL vs OBIO Valuation Comparison 2026 — Intrinsic Value Analysis

NUVL

Biotechnology

Nuvalent, Inc.

Quality

3.7

out of 10

Value Trap

SAFE

Price

$109.27

Last close

Models

10/13

Active

OBIO

Biotechnology

Orchestra BioMed Holdings, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$3.98

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	NUVL Fair Value	NUVL Upside	OBIO Fair Value	OBIO Upside
Bayesian DCF	Intrinsic	$33.87	-69.0%	$1.22	-69.4%
Earnings Power Value	Intrinsic	$45.79	-56.2%	$0.63	-84.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NUVL vs OBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NUVL vs OBIO — Which Stock Is More Undervalued?

OBIO scores higher with a 6.0/10 quality rating vs NUVL's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nuvalent, Inc. (NUVL) and Orchestra BioMed Holdings, Inc. (OBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NUVL currently trades at $109.27 with a QOC of 3.7/10, while OBIO trades at $3.98 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).